Media headlines about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. OraSure Technologies earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 45.574027350623 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
OraSure Technologies (NASDAQ OSUR) opened at $18.06 on Friday. OraSure Technologies has a 12-month low of $10.75 and a 12-month high of $23.01. The company has a market cap of $1,114.47, a PE ratio of 35.41, a PEG ratio of 5.10 and a beta of 1.60.
OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. The business had revenue of $52.00 million during the quarter, compared to the consensus estimate of $50.20 million. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. OraSure Technologies’s revenue was up 46.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.13 EPS. equities analysts anticipate that OraSure Technologies will post 0.29 earnings per share for the current year.
A number of research analysts have recently commented on the stock. BidaskClub raised shares of OraSure Technologies from a “buy” rating to a “strong-buy” rating in a research report on Thursday. ValuEngine raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, December 30th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $24.00 price objective on shares of OraSure Technologies in a research report on Friday, February 2nd. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $22.25.
In related news, Director Stephen S. Phd Tang sold 23,333 shares of OraSure Technologies stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $17.97, for a total transaction of $419,294.01. Following the completion of the sale, the director now owns 59,749 shares of the company’s stock, valued at approximately $1,073,689.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brian Smith sold 20,000 shares of OraSure Technologies stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $17.97, for a total transaction of $359,400.00. Following the sale, the executive vice president now directly owns 28,075 shares of the company’s stock, valued at approximately $504,507.75. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.
WARNING: This report was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/03/17/orasure-technologies-osur-receiving-somewhat-positive-media-coverage-report-shows.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.